相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Innate Immune Cells' Contribution to Systemic Lupus Erythematosus
Andres A. Herrada et al.
FRONTIERS IN IMMUNOLOGY (2019)
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
Fengchun Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Epidemiology of systemic lupus erythematosus: an update
George Stojan et al.
CURRENT OPINION IN RHEUMATOLOGY (2018)
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
A. Doria et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Lupus Nephritis: Current Treatment Paradigm and Unmet Needs
Steven P. Menez et al.
REVIEWS ON RECENT CLINICAL TRIALS (2018)
Pathways of impending disease flare in African-American systemic lupus erythematosus patients
Melissa E. Munroe et al.
JOURNAL OF AUTOIMMUNITY (2017)
The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies
Frances Rees et al.
RHEUMATOLOGY (2017)
Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus
Medha Barbhaiya et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus Pooled Analyses From the Phase III Belimumab Trials
Ronald F. van Vollenhoven et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 20002004
Candace H. Feldman et al.
ARTHRITIS AND RHEUMATISM (2013)
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
M. A. Dooley et al.
LUPUS (2013)
Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes
L. A. Gonzalez et al.
LUPUS (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
The discovery and development of belimumab: the anti-BLyS-lupus connection
William Stohl et al.
NATURE BIOTECHNOLOGY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus
Guillermo J. Pons-Estel et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Revised British isles lupus assessment group 2004 index - A reliable tool for assessment of systemic lupus erythematosus activity
Chee-Seng Yee et al.
ARTHRITIS AND RHEUMATISM (2006)
BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex
H Hase et al.
BLOOD (2004)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
分享论文
